Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. GPCR's valuation appears attractive given a $1B ...
Structure Therapeutics (GPCR) delivered robust Phase 2b results for aleniglipron, surpassing key efficacy and tolerability thresholds for oral GLP-1 therapies. GPCR now appears competitive with top ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results